JP2018503691A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503691A5
JP2018503691A5 JP2017558605A JP2017558605A JP2018503691A5 JP 2018503691 A5 JP2018503691 A5 JP 2018503691A5 JP 2017558605 A JP2017558605 A JP 2017558605A JP 2017558605 A JP2017558605 A JP 2017558605A JP 2018503691 A5 JP2018503691 A5 JP 2018503691A5
Authority
JP
Japan
Prior art keywords
group
uric acid
purine
dihydro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017558605A
Other languages
English (en)
Japanese (ja)
Other versions
JP6678685B2 (ja
JP2018503691A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/000061 external-priority patent/WO2016119570A1/zh
Publication of JP2018503691A publication Critical patent/JP2018503691A/ja
Publication of JP2018503691A5 publication Critical patent/JP2018503691A5/ja
Application granted granted Critical
Publication of JP6678685B2 publication Critical patent/JP6678685B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017558605A 2015-01-30 2016-01-28 尿酸性または痛風性疾患の予防または治療 Active JP6678685B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201510048096 2015-01-30
CN201510048096.3 2015-01-30
CN201510080714.2 2015-02-13
CN201510079809 2015-02-13
CN201510079809.2 2015-02-13
CN201510080714 2015-02-13
CN201510216089.X 2015-04-30
CN201510216089 2015-04-30
PCT/CN2016/000061 WO2016119570A1 (zh) 2015-01-30 2016-01-28 尿酸性或痛风性疾病的预防或治疗

Publications (3)

Publication Number Publication Date
JP2018503691A JP2018503691A (ja) 2018-02-08
JP2018503691A5 true JP2018503691A5 (https=) 2019-03-07
JP6678685B2 JP6678685B2 (ja) 2020-04-08

Family

ID=56542370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558605A Active JP6678685B2 (ja) 2015-01-30 2016-01-28 尿酸性または痛風性疾患の予防または治療

Country Status (26)

Country Link
US (1) US10322132B2 (https=)
EP (1) EP3251675B1 (https=)
JP (1) JP6678685B2 (https=)
KR (1) KR102128810B1 (https=)
CN (1) CN107206002B (https=)
AU (1) AU2016212625B2 (https=)
BR (1) BR112017016065A2 (https=)
CA (1) CA2973746C (https=)
CY (1) CY1124383T1 (https=)
DK (1) DK3251675T3 (https=)
EA (1) EA034139B1 (https=)
ES (1) ES2881872T3 (https=)
HR (1) HRP20211007T1 (https=)
HU (1) HUE054741T2 (https=)
IL (1) IL253726B2 (https=)
LT (1) LT3251675T (https=)
MA (1) MA41431B1 (https=)
MX (1) MX380301B (https=)
PL (1) PL3251675T3 (https=)
PT (1) PT3251675T (https=)
SG (2) SG11201705889VA (https=)
SI (1) SI3251675T1 (https=)
SM (1) SMT202100359T1 (https=)
TW (1) TWI680761B (https=)
WO (1) WO2016119570A1 (https=)
ZA (1) ZA201704600B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12566174B2 (en) 2017-05-11 2026-03-03 The Research Foundation For The State University Of New York Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid
US20260035370A1 (en) 2023-02-27 2026-02-05 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor
CN116650490B (zh) * 2023-06-07 2025-05-20 中国人民解放军海军军医大学 化合物mt-1207在降低尿酸方面的应用
EP4497439A1 (en) * 2023-07-28 2025-01-29 Universitat de les Illes Balears Compounds for the treatment or prevention of gout
TWI902254B (zh) * 2024-05-16 2025-10-21 新加坡商珊頓醫藥科技新加坡公司 化合物8-氯-3-戊基-3,7-二氫-1h-嘌呤-2,6-二酮的晶型及其製備方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
CN101103030B (zh) 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
CN101479273B (zh) * 2006-06-23 2011-11-30 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
KR20090025262A (ko) * 2006-06-23 2009-03-10 인사이트 코포레이션 Hm74a 아고니스트로서 푸리논 유도체
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20110136835A1 (en) * 2009-09-14 2011-06-09 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia

Similar Documents

Publication Publication Date Title
JP2018503691A5 (https=)
JP2016518437A5 (https=)
JP2016516699A5 (https=)
RU2018120242A (ru) Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов
JP2016534063A5 (https=)
CA2687265A1 (en) P70 s6 kinase inhibitors
RU2014136394A (ru) Морфолиноалкилфумаратные соединения, фармацевтические композиции и способы применения
JP2017523225A5 (https=)
JP2016522835A5 (https=)
JP2016540749A5 (https=)
JP2016531861A5 (https=)
JP2015514060A5 (https=)
JP2011500550A5 (https=)
JP2017524704A5 (https=)
JP2017514910A5 (https=)
RU2018142605A (ru) Селективный ингибитор фосфатидилинозитол-3-киназы-гамма
JP2018537535A5 (https=)
JP2015521156A5 (https=)
JP2015520738A5 (https=)
JP2019516739A5 (https=)
RU2018113718A (ru) Новые соединения
JP2019519533A5 (https=)
JP2016522254A5 (https=)
JP2010521516A5 (https=)
JP2018522581A5 (https=)